BRPI0416732A - métodos para a proliferação de cardiomiócitos, e para tratar um distúrbio cardìaco, vetor, composição farmacêutica, e, cardiomiócito - Google Patents

métodos para a proliferação de cardiomiócitos, e para tratar um distúrbio cardìaco, vetor, composição farmacêutica, e, cardiomiócito

Info

Publication number
BRPI0416732A
BRPI0416732A BRPI0416732-5A BRPI0416732A BRPI0416732A BR PI0416732 A BRPI0416732 A BR PI0416732A BR PI0416732 A BRPI0416732 A BR PI0416732A BR PI0416732 A BRPI0416732 A BR PI0416732A
Authority
BR
Brazil
Prior art keywords
cardiomyocyte
cip
vector
proliferation
pharmaceutical composition
Prior art date
Application number
BRPI0416732-5A
Other languages
English (en)
Inventor
Mimi Adachi
Keiichi Nakayama
Shigetaka Kitajima
Hiromitsu Takagi
Original Assignee
Daiichi Asubio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Asubio Pharma Co Ltd filed Critical Daiichi Asubio Pharma Co Ltd
Publication of BRPI0416732A publication Critical patent/BRPI0416732A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

"MéTODOS PARA A PROLIFERAçãO DE CARDIOMIóCITOS, E PARA TRATAR UM DISTúRBIO CARDìACO, VETOR, COMPOSIçãO FARMACêUTICA, E, CARDIOMIóCITO". A proliferação de cardiomiócitos é induzida pela expressão de ciclina e CDK nos cardiomiócitos e pela supressão da função ou ação de uma proteína da família Cip/Kip ou a inibição da produção de uma proteína da família Cip/Kip. Entre as proteínas da família Cip/Kip, é preferível suprimir a função de p27¬ Kip1¬ ou inibir a sua produção. Como um vetor recombinante a ser usado para esse fim, é fornecido um vetor que compreende: (1) um gene da ciclina; (2) um gene da cinase dependente de ciclina; e (3) um ou uma pluralidade selecionada do grupo que consiste de um gene que codifica um fator que inibe a função ou ação de uma proteína da família Cip/Kip e uma seqüência de ácido nucleico que iniba a produção de proteína da família Cip/Kip.
BRPI0416732-5A 2003-11-21 2004-11-19 métodos para a proliferação de cardiomiócitos, e para tratar um distúrbio cardìaco, vetor, composição farmacêutica, e, cardiomiócito BRPI0416732A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003391708 2003-11-21
JP2004246533 2004-08-26
PCT/JP2004/017274 WO2005049822A1 (ja) 2003-11-21 2004-11-19 心筋細胞の増殖方法

Publications (1)

Publication Number Publication Date
BRPI0416732A true BRPI0416732A (pt) 2007-01-16

Family

ID=34622192

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416732-5A BRPI0416732A (pt) 2003-11-21 2004-11-19 métodos para a proliferação de cardiomiócitos, e para tratar um distúrbio cardìaco, vetor, composição farmacêutica, e, cardiomiócito

Country Status (15)

Country Link
US (1) US20070009496A1 (pt)
EP (1) EP1693451B1 (pt)
JP (1) JP4809061B2 (pt)
KR (1) KR101169980B1 (pt)
CN (1) CN1882687B (pt)
AT (1) ATE532863T1 (pt)
AU (1) AU2004291809B2 (pt)
BR (1) BRPI0416732A (pt)
CA (1) CA2545049A1 (pt)
DK (1) DK1693451T3 (pt)
ES (1) ES2376239T3 (pt)
IL (1) IL175264A0 (pt)
RU (1) RU2378375C2 (pt)
SG (1) SG148197A1 (pt)
WO (1) WO2005049822A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090285791A1 (en) * 2008-05-15 2009-11-19 Sbarro Health Research Organization, Inc. Regenerating and enhancing development of muscle tissue
CN102858376A (zh) * 2010-03-12 2013-01-02 第一三共株式会社 使用了微小rna的心肌细胞的增殖方法
EP2640829A4 (en) 2010-11-17 2014-06-11 Univ Kyoto CARDIOMYOCYTE AND / OR CARDIOVORA CELL PROLIFERATING AGENTS AND METHOD FOR PROLIFERATING CARDIOMYOCYTES AND / OR CARDIOVORA CELLS
RU2466391C1 (ru) * 2011-03-28 2012-11-10 Государственное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России) Способ диагностики рецидивирующей кровопотери
EP2714709B1 (en) 2011-05-26 2018-04-18 University of Washington Compositions for use in cell and gene based methods to improve cardiac function
CN102382127A (zh) * 2011-09-23 2012-03-21 复旦大学 特异性促进心肌细胞发生增殖的心肌小分子化合物及其应用
WO2014038655A1 (ja) * 2012-09-07 2014-03-13 国立大学法人京都大学 腸上皮由来体性幹細胞の製造方法
EP3259346B1 (en) * 2015-02-20 2024-08-07 Baylor College of Medicine P63 inactivation for the treatment of heart failure
WO2016164371A1 (en) * 2015-04-07 2016-10-13 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods for inducing cell division of postmitotic cells
CN110907644B (zh) * 2019-12-11 2023-01-06 深圳市达科为生物工程有限公司 多种细胞鉴定试剂盒及操作方法
CN113061573B (zh) * 2021-05-21 2023-03-24 苏州大学 间歇性饥饿促进心肌细胞成熟的方法
CN117159580A (zh) * 2023-08-14 2023-12-05 中山大学附属第一医院 Cip的抑制剂在制备治疗心肌梗塞的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU687117B2 (en) * 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
GB9417366D0 (en) * 1994-08-26 1994-10-19 Prolifix Ltd Cell cycle regulated repressor and DNA element
EP1126866B1 (en) * 1998-11-02 2007-02-07 The Regents of The University of California A mutant phospholamban molecule and its use in the treatment of cardiac disease and heart failure
US7795032B2 (en) * 2001-05-17 2010-09-14 Masaaki Ikeda Methods for proliferating cardiomyocytes and recombinant vectors therefor
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization

Also Published As

Publication number Publication date
EP1693451A4 (en) 2007-11-07
DK1693451T3 (da) 2012-02-13
CN1882687B (zh) 2012-07-04
WO2005049822A1 (ja) 2005-06-02
JP4809061B2 (ja) 2011-11-02
ATE532863T1 (de) 2011-11-15
AU2004291809B2 (en) 2010-05-20
RU2378375C2 (ru) 2010-01-10
JPWO2005049822A1 (ja) 2007-06-07
AU2004291809A1 (en) 2005-06-02
EP1693451A1 (en) 2006-08-23
RU2006121980A (ru) 2007-12-27
SG148197A1 (en) 2008-12-31
EP1693451B1 (en) 2011-11-09
US20070009496A1 (en) 2007-01-11
KR20060125760A (ko) 2006-12-06
IL175264A0 (en) 2006-09-05
CA2545049A1 (en) 2005-06-02
CN1882687A (zh) 2006-12-20
KR101169980B1 (ko) 2012-07-31
ES2376239T3 (es) 2012-03-12

Similar Documents

Publication Publication Date Title
BRPI0416732A (pt) métodos para a proliferação de cardiomiócitos, e para tratar um distúrbio cardìaco, vetor, composição farmacêutica, e, cardiomiócito
PT1548032E (pt) Péptidos kdr e vacinas que os contêm
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
Huang et al. Fish TRIM35 negatively regulates the interferon signaling pathway in response to grouper nodavirus infection
Saccomanno et al. The cytoplasm of Xenopus oocytes contains a factor that protects double-stranded RNA from adenosine-to-inosine modification
BURTON et al. Actin detected in mouse neuroblastoma cells by binding of heavy meromyosin
SI2718434T1 (en) Compositions and methods for treating celiac sprue disease
BR112021026292A2 (pt) Cistationina beta sintase peguilada para terapia enzimática para tratamento de homocistinúria
Pizzo et al. The success of the RNase scaffold in the advance of biosciences and in evolution
Zhang et al. Expression of avian β-defensin mRNA in the chicken yolk sac
EP0232523A3 (en) Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins
Sarkar et al. The curious case of SARM1: Dr. Jekyll and Mr. Hyde in cell death and immunity?
Casterlow et al. An antimicrobial peptide is downregulated in the small intestine of Eimeria maxima-infected chickens
Cheng et al. Identification and functional analysis of epidermal growth factor receptor (EGFR) from Scylla paramamosain: The first evidence of two EGFR genes in animal and their involvement in immune defense against pathogen infection
Zhou et al. Identification and functional analysis of transforming growth factor-β type I receptor (TβR1) from Scylla paramamosain: the first evidence of TβR1 involved in development and innate immunity in crustaceans
Barnes et al. Two hepcidin-like antimicrobial peptides in Barramundi Lates calcarifer exhibit differing tissue tropism and are induced in response to lipopolysaccharide
Shao et al. Pigeon MDA5 inhibits viral replication by triggering antiviral innate immunity
de Oliveira et al. Beta-defensin genes of the Colubridae snakes Phalotris mertensi, Thamnodynastes hypoconia, and T. strigatus
Tatsumi et al. 2′, 5′-oligoadenylate synthetase gene in chicken: gene structure, distribution of alleles and their expression
Zhang et al. PQBP1 regulates the cellular inflammation induced by avian reovirus and interacts with the viral p17 protein
BR0314986A (pt) Sequência de polinucleotìdeo, vetor de expressão, composição farmacêutica, usos de uma sequência de polinucleotìdeo, de um vetor e de uma composição, e, método para tratar ou prevenir infecções pelo hpv ou qualquer sintomas ou doenças associados com elas
Wu et al. Molecular cloning and expression analysis of a β-thymosin homologue from a gastropod abalone, Haliotis diversicolor supertexta
Watanabe et al. Structural and functional analyses of chicken liver ferritin
WO2007071248A3 (en) Neuritogenic and neuronal survival promoting peptides derived from the family of s-100 proteins
Yoshitome et al. Mr 25 000 protein, a substrate for protein serine/threonine kinases, is identified as a part of Xenopus laevis vitellogenin B1

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: DAIICHI SANKYO COMPANY LIMITED (JP)

Free format text: TRANSFERIDO POR INCORPORACAO DE : ASUBIO PHARMA CO., LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]